Amende I, Bentivegna L A, Zeind A J, Wenzlaff P, Grossman W, Morgan J P
Charles A. Dana Research Institute, Boston, MA.
J Clin Invest. 1992 Jun;89(6):2060-5. doi: 10.1172/JCI115818.
Ischemia-induced ventricular dysfunction has been shown to be associated with increased diastolic and systolic intracellular concentrations of free, ionized calcium ([Ca2+]i). The present study was designed to determine the effects of the Ca2+ antagonist nisoldipine on the relationship between [Ca2+]i and left ventricular contraction and relaxation during ischemia and reperfusion on a beat-to-beat basis. Nine isovolumic coronary-perfused ferret hearts were made globally ischemic for 3 min and reperfused for 10 min. Ischemia and reperfusion were repeated during perfusion with a buffer containing 10(-8) M nisoldipine. From left ventricular developed pressure, time to peak pressure and time to 50% pressure decline were obtained. [Ca2+]i was determined with the bioluminescent protein aequorin. Global ischemia caused a rapid decline in contractile function and a significant increase in diastolic [Ca2+]i, from 0.35 to 0.81 microM, and in systolic [Ca2+]i, from 0.61 to 0.96 microM. During reperfusion, [Ca2+]i returned to baseline while ventricular function was still impaired. Relaxation was more affected than systolic contractile function. Nisoldipine significantly reduced the ischemia-induced rise in diastolic [Ca2+]i to 0.62 microM, and in systolic [Ca2+]i to 0.77 microM, and lessened the decrease in contractile function. Nisoldipine significantly accelerated the decline in [Ca2+]i during reperfusion and improved recovery of contractility and relaxation. These effects were associated with a significant diminution in ischemic lactate production. Taken together, our results provide direct quantitative evidence on a beat-to-beat basis that the calcium antagonist nisoldipine can ameliorate ischemia-induced abnormalities in [Ca2+]i handling, an effect that was associated with improved myocardial function during early reperfusion.
缺血诱导的心室功能障碍已被证明与舒张期和收缩期细胞内游离离子钙([Ca2+]i)浓度升高有关。本研究旨在确定钙拮抗剂尼索地平对缺血和再灌注期间逐搏[Ca2+]i与左心室收缩和舒张关系的影响。9只等容冠状动脉灌注的雪貂心脏进行全心缺血3分钟,再灌注10分钟。在含10(-8) M尼索地平的缓冲液灌注期间重复缺血和再灌注。从左心室舒张末压获得压力峰值时间和压力下降50%的时间。用生物发光蛋白水母发光蛋白测定[Ca2+]i。全心缺血导致收缩功能迅速下降,舒张期[Ca2+]i从0.35 microM显著增加到0.81 microM,收缩期[Ca2+]i从0.61 microM增加到0.96 microM。再灌注期间,[Ca2+]i恢复到基线水平,而心室功能仍受损。舒张功能比收缩功能受影响更大。尼索地平显著降低缺血诱导的舒张期[Ca2+]i升高至0.62 microM,收缩期[Ca2+]i升高至0.77 microM,并减轻收缩功能下降。尼索地平显著加速再灌注期间[Ca2+]i的下降,并改善收缩性和舒张功能的恢复。这些作用与缺血乳酸产生的显著减少有关。综上所述,我们的结果提供了直接的定量证据,表明钙拮抗剂尼索地平可改善缺血诱导的[Ca2+]i处理异常,这种作用与早期再灌注期间心肌功能的改善有关。